electroCore, Inc. (ECOR) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects mixed signals. Basic financial performance shows slight improvement in adjusted EBITDA net loss, but there's a delay in profitability. Product development is active, but with uncertainties in TAC-STIM and international revenue. Market strategy is cautious, with some success in VA channels. Expenses are increasing, impacting financial health. Shareholder returns are not addressed. Q&A reveals cautious expansion and litigation issues. Overall, the stock price reaction is likely neutral due to balanced positive and negative elements.
Key Financial Performance
Revenue Revenue reached a record $8.7 million in Q3 2025, up 33% year-over-year and 18% sequentially. This growth was driven by higher sales of prescription devices and growth in the company's non-prescription general wellness Truvaga product.
Gross Margin Gross margins remained strong at 86%, up slightly from 84% last year. This improvement reflects operational efficiencies and product mix.
Prescription Device Revenue Prescription device revenue grew 19% year-over-year to $6.8 million, driven by both gammaCore and Quell sales in the VA hospital system. The increase is attributed to expanded adoption and sales efforts.
Health and Wellness Product Revenue Health and wellness product revenue reached $1.9 million, a 54% increase sequentially and 121% year-on-year. This includes a $500,000 onetime Truvaga order for a third-party clinical trial. Excluding that, Truvaga revenue grew 18% sequentially and 79% year-on-year, driven by a shift away from Amazon and increased focus on direct-to-consumer platforms.
Operating Expenses Total operating expenses in Q3 2025 were approximately $10.4 million, up from $8.1 million in Q3 2024. The increase was primarily due to greater investment in selling and marketing costs, consistent with the company's increase in sales.
Net Loss GAAP net loss in Q3 2025 was $3.4 million, compared to a net loss of $2.5 million in Q3 2024. The increase in net loss is attributed to an increase in other expenses related to the CVR liability and interest expense on convertible debt financing.
Adjusted EBITDA Net Loss Adjusted EBITDA net loss in Q3 2025 was $2 million, compared to $2.1 million in Q3 2024. This slight improvement reflects operational efficiencies despite increased investments.
Cash Balance Cash balance as of September 30, 2025, was $13.2 million, up from $12.2 million as of December 31, 2024. The increase is due to securing a term debt facility and a private placement.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Truvaga: Sales returned to growth, driven by e-commerce and affiliate networks. Revenue reached $1.9 million, a 54% sequential increase and 121% year-on-year. Truvaga has sold over 19,000 handsets, powering 1.6 million user sessions on its mobile app.
Quell Fibromyalgia: Acquired from NeuroMetrix and launched in July 2025. Early performance exceeded expectations, with third and fourth quarter results projected to cover acquisition costs and support future revenue growth.
gammaCore: Prescription device sales grew 19% year-over-year to $6.8 million, driven by VA hospital system adoption. 12,000 devices dispensed, addressing 2% of the VA headache market.
VA hospital system: Secured a new 5-year contract, upgraded from a 3-year agreement. Expanded sales team and strategies to boost adoption. VA revenue growth resumed after a temporary slowdown.
China market: Broadened options outside the U.S. through a royalty-based arrangement with a China-based investor. No capital investment required from electroCore.
Managed care systems: Finalized a contract providing access and coverage for therapies. Modest investment in a dedicated sales team to create sustained revenue streams.
Revenue growth: Third quarter revenue reached $8.7 million, up 33% year-over-year and 18% sequentially. Gross margins remained strong at 86%.
Strategic investments: Invested in sales, marketing, and product development to accelerate growth. Added new Board members and partnered with AI firm StratejAI to enhance wellness app.
NeuroMetrix acquisition: Acquired Quell portfolio, diversifying offerings and mitigating product risk. Added FDA-cleared Quell Fibromyalgia and Quell Relief brands.
AI and software integration: Partnered with StratejAI to develop personalized, data-driven user experiences for wellness products, aiming to establish recurring revenue streams.
International expansion: Focused on EU, Middle East, and China markets through strategic partnerships and Board expertise.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Profitability Delays: The company has chosen to delay profitability until the second half of 2026 to prioritize growth and long-term value creation. This decision involves increased operating expenses and investments in marketing, sales, and product development, which could strain cash flow and financial stability in the short term.
Regulatory and Commercialization Risks: The company's expansion into international markets, including China, depends on local regulatory processes and commercialization efforts by third parties. Delays or failures in these processes could impact revenue growth and market penetration.
Patent Infringement Dispute: A potential patent and trademark infringement by a Truvaga copycat from Eastern Europe has led to legal action. This ongoing dispute could result in financial and reputational risks.
Customer Concentration Risk: The VA hospital system remains the largest customer, accounting for a significant portion of revenue. Over-reliance on this channel poses a risk if demand fluctuates or external factors impact this relationship.
Macroeconomic and Political Factors: The company experienced a temporary slowdown in VA revenue growth in Q4 2024 due to external macroeconomic and political factors. Similar disruptions could occur in the future, affecting revenue stability.
Increased Operating Expenses: Operating expenses have risen due to investments in sales, marketing, and product development. This could pressure margins and delay the path to profitability if revenue growth does not meet expectations.
Competition and Market Dynamics: The company faces competition in the noninvasive vagus nerve stimulation market and the broader wellness market. Failure to differentiate its products or respond to competitive pressures could impact market share and revenue.
Cash Flow Management: The company forecasts using approximately $5 million in cash to fund operations in the first nine months of 2026. Any deviation from revenue projections could lead to liquidity challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company is increasing full-year 2025 revenue guidance to $31.5 million to $32.5 million.
Profitability Timeline: The company expects to achieve positive adjusted EBITDA in the second half of 2026, with quarterly revenue reaching approximately $12 million.
Cash Balance: The company forecasts a cash balance of approximately $10.5 million as of December 31, 2025.
Growth Investments: Investments are being made in people, marketing, and product development to accelerate growth and scale in 2026 and 2027.
VA Hospital Channel Expansion: The company plans to add W-2 and 1099 staff in select locations through 2026 to grow the VA hospital business.
Managed Care System Growth: The company is investing in sales talent to focus on a large commercial managed care system, with gammaCore Sapphire added to a managed care system contract.
Health and Wellness Division: The company is developing new health and wellness offerings, including Quell Relief for lower extremity pain, and enhancing its Truvaga platform with marketing and promotional investments.
AI and Software Integration: Development of next-generation applications to complement Truvaga and Quell is underway, aiming to create personalized data-driven user experiences and new recurring revenue streams.
International Expansion: The company is broadening its opportunities outside the U.S. through a royalty-based arrangement in China and leveraging connections in the EU and Middle East for expansion.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What channels was NeuroMetrix selling into before the acquisition of Quell?
A:The prescription Quell for fibromyalgia was sold in 4 or 5 VA hospitals off contract through open market access prior to the acquisition. There were also a few cash pay customers served through HealthWarehouse, a PDM, but in small numbers.
Q:Can you provide further details on the Truvaga sale for a clinical trial?
A:The sale is for one clinical trial being run in long COVID subjects. It is a large trial with various therapies being evaluated. However, as it is an investigator-initiated trial, NeuroMetrix does not have much information about it, including the protocol.
Q:What is the status of the next-gen mobile app being developed?
A:The next update of the app will be Truvaga Plus only. It will work with the legacy Truvaga Plus but is not set up to work with gammaCore or Quell. Quell has its own mobile app environment. Plans to harmonize the various mobile apps for vagus nerve stimulation and Quell fibromyalgia apps will take more time.
Q:What factors are contributing to the success of Quell fibromyalgia in the VA space?
A:The success is attributed to the safety profile of the product, the unmet clinical need for fibromyalgia patients, and the willingness of pain and polytrauma specialists to adopt the solution. The production facility was moved to Rockaway, New Jersey, and the product was added to the VA hospital contract, enabling faster uptake.
Q:How easy is it to replicate the success of Quell fibromyalgia in other segments like Kaiser Permanente?
A:The company is proceeding cautiously. They have just secured a contract with a large managed care system (not named but implied to be Kaiser) for gammaCore Sapphire. They have not yet attempted to bring Quell fibromyalgia to that system but plan to do so after gaining traction.
Q:What are the expectations for TAC-STIM in terms of Air Force procurement?
A:Revenue generation for TAC-STIM remains small and lumpy. In Q3, $140,000 of revenue was generated, but Q4 has been impacted by the government shutdown. The internal forecast for 2026 is $400,000, with potential upside, but the timing of large orders is uncertain.
Q:What is the plan for commercializing the Chinese market?
A:The company does not plan to commercialize in China. Instead, Mr. Zhang, who owns 10% of electroCore, has a license to commercialize the technology in China. He plans to go through the CFDA process with a product of his own design, manufactured in China, and will pay royalties to electroCore.
Q:Is the current growth in the VA segment coming from new accounts or increased utilization from existing customers?
A:Growth is coming from both new accounts and increased utilization from existing customers. Over the past year, almost 40 new VA hospitals were added, and Quell fibromyalgia contributed meaningful revenue.
Q:What are the geographical areas with the most growth potential in the VA system?
A:The company is strong in Texas, the Southeast, and the West Coast. New England, Mid-Atlantic, and the rest of the Midwest are considered greenfield territories with growth potential.
Q:What is the update on the clinical development pipeline and new indications?
A:The company is focusing on PTSD with meetings held with the FDA and plans for a pivotal trial next year. They are also planning for mild traumatic brain injury (2027 initiative), neuropathy secondary to chemotherapy, and low back pain (2026 initiative).
Q:What is the status of the Quell royalty payments?
A:The Quell royalty is capped. For the current year, the income statement effect will decline quarter-over-quarter and year-over-year. Payments are adjusted as estimates and will be paid in May or June of next year.
Q:What is being done to combat copycat marketing of vagus nerve stimulation devices?
A:The company has filed a lawsuit against Pulsetto for patent infringement and other trade-related issues. The case is in Federal Court District of New Jersey, and the company is focusing on winning the litigation.
Q:What were the neuro revenue contributions for Q3?
A:Quell fibromyalgia contributed $595,000, and Truvaga contributed $1,674,000 in net revenue for Q3.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the expected number of additional VA hospitals prescribing in 2026, stating it was a 'secret.'
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Avenue Capital
CVR liability
Chairman
Dr
ECOR
FDA device
Microsoft Google
Pivot
Quell Fibromyalgia
Quell Relief
Quell user
VNS
Wellness
arrangement
care system
cash balance
connection
debt financing
decision
division
expense debt
expense month
experience stream
expertise
financing Avenue
founder
income
interest expense
investor
member
outlet
royalty
software
technology
value
ECOR Transcript
electroCore, Inc. (ECOR) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
Neutral6-23
electroCore, Inc. (ECOR) Q1 2026 Earnings Call Transcript
Positive5-7
The company's financial performance showed strong revenue growth and improved gross margins, indicating operational efficiency. Although there was a net loss, it was reduced compared to the previous year. The absence of strategic, risk, or return discussions doesn't negatively impact the sentiment, as the financial metrics alone are positive. The lack of Q&A insights doesn't alter this view. Overall, the earnings report suggests a positive outlook, likely leading to a stock price increase in the short term.
electroCore, Inc. (ECOR) Q4 2025 Earnings Call Transcript
Positive3-19
The earnings call reveals strong financial performance with significant revenue growth and improved gross margins. Despite increased expenses, adjusted EBITDA shows improvement. The Q&A highlights strategic growth plans in the VA and DTC channels, with new leadership potentially enhancing federal channel efficiency. While management's guidance was vague on some points, the overall sentiment is positive, supported by partnerships and product launches. These factors suggest a likely positive stock price movement, especially given the strong revenue growth and strategic initiatives.
electroCore, Inc. (ECOR) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reflects mixed signals. Basic financial performance shows slight improvement in adjusted EBITDA net loss, but there's a delay in profitability. Product development is active, but with uncertainties in TAC-STIM and international revenue. Market strategy is cautious, with some success in VA channels. Expenses are increasing, impacting financial health. Shareholder returns are not addressed. Q&A reveals cautious expansion and litigation issues. Overall, the stock price reaction is likely neutral due to balanced positive and negative elements.
ECOR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
